Strategic Partnerships Hyloris actively pursues licensing and co-development opportunities, exemplified by recent exclusive worldwide development and commercialization agreements with RedHill Biopharma for RHB-102 (Bekinda). This indicates a readiness to engage with pharma partners to accelerate market access for repurposed or reformulated assets.

Repurposing Focus The company specializes in reinventing existing medicines through reformulation and repurposing, leveraging established regulatory pathways to shorten timelines and reduce risk. This positions Hyloris as a value-add partner for payors and clinicians seeking faster access to improved therapies.

Diversified Portfolio With a broad portfolio of 28 products and a pipeline over 30 programs, including early-stage assets and two in collaboration with partners like Sotalol IV and Maxigesic IV, there are multiple entry points for co-development, licensing, and regional commercialization opportunities.

Regulatory Leverage Hyloris prioritizes pathways such as FDA 505(b)(2) and equivalent routes in other regions, which can be attractive to strategic buyers seeking faster product-to-market timelines and reduced development risk.

Global Expansion Readiness Based in Belgium with a Brussels listing and partnerships across regions, Hyloris demonstrates a capability to operate in international markets, offering potential for sales expansion through regional co-marketing deals, distribution agreements, or strategic collaborations in Europe, North America, and beyond.